MY201837A - Polyionic infusion solution - Google Patents
Polyionic infusion solutionInfo
- Publication number
- MY201837A MY201837A MYPI2020001143A MYPI2020001143A MY201837A MY 201837 A MY201837 A MY 201837A MY PI2020001143 A MYPI2020001143 A MY PI2020001143A MY PI2020001143 A MYPI2020001143 A MY PI2020001143A MY 201837 A MY201837 A MY 201837A
- Authority
- MY
- Malaysia
- Prior art keywords
- polyionic
- infusion solution
- polyionic infusion
- sodium
- solution
- Prior art date
Links
- 239000003978 infusion fluid Substances 0.000 title abstract 3
- 229920000831 ionic polymer Polymers 0.000 title abstract 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000141 anti-hypoxic effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 150000001805 chlorine compounds Chemical class 0.000 abstract 1
- AEKLPNAELPOQBI-RHLRHBBGSA-L disodium butanedioate (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].C(CCC(=O)[O-])(=O)[O-].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Na+] AEKLPNAELPOQBI-RHLRHBBGSA-L 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002443 hepatoprotective effect Effects 0.000 abstract 1
- 231100000566 intoxication Toxicity 0.000 abstract 1
- 230000035987 intoxication Effects 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2017135900A RU2676761C1 (ru) | 2017-10-09 | 2017-10-09 | Полиионный инфузионный раствор |
| PCT/RU2018/050119 WO2019074404A1 (ru) | 2017-10-09 | 2018-10-04 | Полиионный инфузионный раствор |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY201837A true MY201837A (en) | 2024-03-19 |
Family
ID=65024999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020001143A MY201837A (en) | 2017-10-09 | 2018-10-04 | Polyionic infusion solution |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN111372573B (ru) |
| BR (1) | BR112020006585A2 (ru) |
| CL (1) | CL2020000971A1 (ru) |
| CO (1) | CO2020005293A2 (ru) |
| EA (1) | EA035241B1 (ru) |
| GE (1) | GEP20207073B (ru) |
| MY (1) | MY201837A (ru) |
| PH (1) | PH12020550196A1 (ru) |
| RU (1) | RU2676761C1 (ru) |
| UA (1) | UA146728U (ru) |
| WO (1) | WO2019074404A1 (ru) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5366730A (en) * | 1989-12-20 | 1994-11-22 | Boehringer Mannheim Gmbh | Stabilized compositions having human tissue type plasminogen activator enzymatic activity |
| EA000879B1 (ru) * | 1998-12-02 | 2000-06-26 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Инфузионный раствор "реамберин" |
| RU2240116C1 (ru) * | 2003-08-20 | 2004-11-20 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Дезинтоксикационный инфузионный раствор |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| CN102600070B (zh) * | 2011-12-22 | 2014-08-27 | 湖北德康药业有限公司 | 环磷腺苷葡胺组合物注射液及其制备方法 |
| RU2536994C1 (ru) * | 2013-05-17 | 2014-12-27 | Общество С Ограниченной Ответственностью "Нпо "Нефрон" | Концентрированный кислотный компонент, набор для его получения, концентрированный раствор кислотного компонента для получения гемодиализирующего раствора и способ его получения |
| CN104224829A (zh) * | 2014-09-23 | 2014-12-24 | 四川科伦药业股份有限公司 | 一种钠钾镁钙葡萄糖注射液及其制备方法 |
| CN105213329B (zh) * | 2015-11-10 | 2018-03-27 | 瑞阳制药有限公司 | 注射用环磷腺苷葡胺冻干粉针及其制备方法 |
-
2017
- 2017-10-09 RU RU2017135900A patent/RU2676761C1/ru active
-
2018
- 2018-02-20 EA EA201800110A patent/EA035241B1/ru unknown
- 2018-10-04 WO PCT/RU2018/050119 patent/WO2019074404A1/ru not_active Ceased
- 2018-10-04 MY MYPI2020001143A patent/MY201837A/en unknown
- 2018-10-04 BR BR112020006585-4A patent/BR112020006585A2/pt not_active IP Right Cessation
- 2018-10-04 CN CN201880075843.4A patent/CN111372573B/zh active Active
- 2018-10-08 UA UAA201810017U patent/UA146728U/uk unknown
- 2018-10-09 GE GEAP201814899A patent/GEP20207073B/en unknown
-
2020
- 2020-04-01 PH PH12020550196A patent/PH12020550196A1/en unknown
- 2020-04-09 CL CL2020000971A patent/CL2020000971A1/es unknown
- 2020-04-28 CO CONC2020/0005293A patent/CO2020005293A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2676761C1 (ru) | 2019-01-11 |
| WO2019074404A1 (ru) | 2019-04-18 |
| UA146728U (uk) | 2021-03-17 |
| EA035241B1 (ru) | 2020-05-20 |
| CN111372573A (zh) | 2020-07-03 |
| BR112020006585A2 (pt) | 2020-10-06 |
| PH12020550196A1 (en) | 2021-03-01 |
| GEAP201914899A (ru) | 2019-10-10 |
| EA201800110A1 (ru) | 2019-04-30 |
| CL2020000971A1 (es) | 2020-08-21 |
| CN111372573B (zh) | 2022-04-29 |
| GEP20207073B (en) | 2020-02-25 |
| CO2020005293A2 (es) | 2020-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003437A1 (es) | Formulaciones de dosis fija. | |
| PH12018502268A1 (en) | Amide-substituted pyridinyltriazole derivatives and uses thereof | |
| MY174635A (en) | Fast disintegrating solid dosage form formulation comprising functionalized calcium carbonate and method of their manufacture | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| MX2020002806A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso. | |
| BR112018008965A8 (pt) | terapia de reposição de plasminogênio para deficiência de plasminogênio | |
| CR20200291A (es) | Composiciones y métodos para el tratamiento de enfermedades metabólicas | |
| GEAP201914546A (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| MX2019008489A (es) | Tratamiento que comprende la administracion oral o gastrica de edaravona. | |
| JOP20220002B1 (ar) | عمليات ومركب وسيط لتحضير واسع النطاق لـ 2، 4، 6-تراي فلورو-n-[6-(1-ميثيل-بيبريدين-4-كاربونيل)-بيريدين-2-يل]-بنزاميد هيمي سكسينات، وتحضير 2، 4، 6-تراي فلورو-n-[6-(1-ميثيل-بيبريدين-4-كاربونيل)-بيريدين-2-يل]-بنزاميد أسيتات | |
| PH12016501357B1 (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| UY38345A (es) | Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g | |
| EA202191683A1 (ru) | Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии | |
| MY195694A (en) | Carboxylic Acid URAT1 Inhibitor Containing Diarylmethane Structure, Preparation Method and use Thereof | |
| NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| BR112017013845A2 (pt) | derivados de glucagon | |
| EA201991490A1 (ru) | Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1 | |
| WO2018097570A3 (ko) | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 | |
| PH12013500077A1 (en) | Medicinal agent for prevention and/or treatment of hepatocellular carcinoma | |
| PH12020550196A1 (en) | Polyionic infusion solution | |
| MX2015014646A (es) | Compuesto de acetamida heterociclica. | |
| MX2019004822A (es) | Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo. | |
| MY201954A (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate |